Trade Vir Biotechnology ^VIR

Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48

Is Vir Biotechnology (VIR) Overvalued After Its 127% Run?

Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain

Vir Biotechnology (VIR) Says Its Hepatitis Delta Therapy Met All Phase 3 Endpoints

VIR Reiterates by HC Wainwright & Co. -- Price Target Maintained

Vir hepatitis D drug succeeds in first pivotal study

HC Wainwright Reaffirms "Buy" Rating for Vir Biotechnology (NASDAQ:VIR)

Vir Biotechnology Stock Jumps 14%

Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - Time to Buy?

Vir Biotechnology (VIR) Stock Jumps 13% After Phase 3 Hepatitis Delta Win

Vir Stock Soars After Late-Stage Trial Win. Why Biotech Could Be

Vir Biotechnology stock jumps 22% after hepatitis delta Phase 3 trial success

VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever - Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets

Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data | Morningstar

Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta | Morningstar

Vir Biotechnology (NASDAQ:VIR) Upgraded to Buy at Wall Street Zen - Daily Political

Vir Biotechnology Stock Gets Focus As Phase 3 Hepatitis Delta Data Head To AASLD

Vir Biotechnology (NASDAQ:VIR) Shares Cross Above 50 Day Moving Average - Should You Sell?

Vir Biotechnology (NASDAQ:VIR) Upgraded at Wall Street Zen

Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High on Analyst Upgrade

Vir Biotechnology (NASDAQ:VIR) Sets New 12-Month High Following Analyst Upgrade - Zolmax

Vir Biotechnology (NASDAQ:VIR) Raised to "Hold" at Zacks Research - Zolmax

Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Zacks Research

Needham & Company LLC Issues Positive Forecast for Vir Biotechnology (NASDAQ:VIR) Stock Price

Vir Biotechnology Inc (VIR) (Q3 2026) Earnings Call Highlights: Hepatitis Delta Data on Deck ...

Narrower Losses Could Be A Game Changer For Vir Biotechnology (VIR)

What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call - Daily Political

Vir Biotechnology (NASDAQ:VIR) Releases Quarterly Earnings Results, Beats Expectations By $0.18 EPS

Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells $15,216.19 in Stock

Vir Biotechnology (NASDAQ:VIR) EVP Sells $26,717.70 in Stock - Stock Observer

Vir Biotechnology (NASDAQ:VIR) Stock: Insider Verneuil Vanina De Sells 1,343 Shares - Daily Political

Head-To-Head Review: Vir Biotechnology (NASDAQ:VIR) & BioCryst Pharmaceuticals (NASDAQ:BCRX) - Daily Political

Vir Biotechnology (NASDAQ:VIR) Reaches New 52-Week High - Should You Buy?

Vir Biotechnology (NASDAQ:VIR) Shares Gap Down - What's Next?

Gilead Cancer Deal Could Be A Game Changer For Vir Biotechnology (VIR)

Vir Biotechnology (NASDAQ:VIR) Shares Gap Down - Here's What Happened - Stock Observer

Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Wednesday

Vir Biotechnology (NASDAQ:VIR) Shares Cross Above 50-Day Moving Average - What's Next?

Is Vir Biotechnology (VIR) Undervalued On Its Gilead Oncology Deal?

Comparing Vir Biotechnology (NASDAQ:VIR) and REGENXBIO (NASDAQ:RGNX) - Markets Daily

Vir Biotechnology, Inc. (VIR) - What Are Investment Firms Thinking About This Stock?

Hepatitis B Virus (HBV) Infection Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Ascletis Pharma, Shanghai HEP Pharma, Romark Lab, GSK | ABNewswire

Vir Biotechnology (NASDAQ:VIR) & REGENXBIO (NASDAQ:RGNX) Head-To-Head Survey - Stock Observer

Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative? - Simply Wall St News

Could Vir Biotechnology (VIR) Be Above Fair Value After Recent Pipeline News?

I'm Taking Out Some 'Insurance' on My Portfolio With These 2 Stocks

What Could Gilead Sciences (GILD) New Solid Tumor Partnership Mean For Oncology?

Gilead Sciences, Inc. $GILD Stake Trimmed by Curated Wealth Partners LLC - Zolmax

Vir Biotechnology and Gilead Sciences Forge $1.88 Billion Collaboration for Solid Tumor Cancer Therapies, ETPharma

Vir partners with Gilead in $1.8B+ deal for T-cell engagers

Verastem focuses on KRAS G12D therapy, reports 41% ORR in PDAC

Vir Biotechnology Partners With Gilead On Next-Generation Cancer Immunotherapy Programs

Vir Biotechnology Shares Jump on Gilead Cancer Collaboration | Morningstar

Vir CEO sees 'opportunity to do more deals' after striking $1.9B Gilead pact for dual-masked TCEs

Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - What's Next? - Daily Political

Is FDA Fast Track Status Altering The Investment Case For Vir Biotechnology (VIR)?